BR100 Increased By (0.66%)
BR30 Increased By (0.37%)
KSE100 Increased By (0.46%)
KSE30 Increased By (0.45%)
AGHA 7.78 Increased By ▲ 0.03 (0.39%)
BECO 5.20 Increased By ▲ 0.01 (0.19%)
BML 58.19 Decreased By ▼ -0.47 (-0.8%)
BOP 34.16 Increased By ▲ 0.47 (1.4%)
CNERGY 10.62 Increased By ▲ 0.01 (0.09%)
CSIL 5.43 Increased By ▲ 0.13 (2.45%)
FCCL 54.62 Increased By ▲ 0.88 (1.64%)
FFL 16.67 Increased By ▲ 0.21 (1.28%)
FNEL 1.27 Increased By ▲ 0.05 (4.1%)
KEL 7.40 Increased By ▲ 0.12 (1.65%)
KOSM 5.79 Increased By ▲ 0.15 (2.66%)
LOTCHEM 29.69 Increased By ▲ 0.04 (0.13%)
MLCF 95.25 Decreased By ▼ -1.11 (-1.15%)
NBP 203.71 Increased By ▲ 0.18 (0.09%)
NCPL 57.80 Increased By ▲ 0.95 (1.67%)
NPL 69.01 Increased By ▲ 1.70 (2.53%)
OGDC 316.51 Decreased By ▼ -1.71 (-0.54%)
PACE 10.71 Increased By ▲ 0.08 (0.75%)
PAEL 42.85 Increased By ▲ 1.08 (2.59%)
PIBTL 16.81 No Change ▼ 0.00 (0%)
PPL 220.05 Decreased By ▼ -0.12 (-0.05%)
PRL 50.80 Increased By ▲ 1.75 (3.57%)
PTC 70.62 Increased By ▲ 0.61 (0.87%)
SSGC 28.50 Decreased By ▼ -0.64 (-2.2%)
TBL 9.87 Increased By ▲ 0.10 (1.02%)
TELE 8.86 Increased By ▲ 0.04 (0.45%)
TPL 18.30 Increased By ▲ 1.13 (6.58%)
TPLP 12.89 Increased By ▲ 0.38 (3.04%)
TREET 22.65 Increased By ▲ 0.06 (0.27%)
TRG 59.92 Decreased By ▼ -0.30 (-0.5%)
Business & Finance

EU says discussions will continue with AstraZeneca to get more vaccines in Q1

  • The Commission president Ursula von der Leyen said AstraZeneca had raised its target of supplies to the EU to 40 million doses from 31 million until the end of March, after a large cut last week.
  • Its original commitment was of at least 80 million doses, and possibly up to 120 million in the first quarter.
Published Updated
By

BRUSSELS: The European Commission will continue discussions with AstraZeneca with the purpose of receiving more doses of its COVID-19 vaccine than the company has so far pledged in the first quarter of the year, a spokesman said on Monday.

On Sunday, the Commission president Ursula von der Leyen said AstraZeneca had raised its target of supplies to the EU to 40 million doses from 31 million until the end of March, after a large cut last week.

Its original commitment was of at least 80 million doses, and possibly up to 120 million in the first quarter, EU sources told Reuters last week.

The offer by AstraZeneca was an improvement but "it is definitely not the amount which we expect to receive until the end of the first quarter, so of course discussions will continue," the spokesman told a news conference.

Comments

Comments are closed for this article.